This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: February 20, 2007
Last updated: November 17, 2010
Last verified: November 2010
To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.

Condition Intervention Phase
Glomerulonephritis Drug: Ramipril Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy) [ Time Frame: From the beginning to the end of the study ]
  • Development of proteinuria [ Time Frame: From the beginning to the end of the study ]
  • 20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation [ Time Frame: From the beginning to the end of the study ]
  • body weight, blood pressure, pulse [ Time Frame: From the beginning to the end of the study ]
  • Adverse effects of treatment [ Time Frame: From the beginning to the end of the study ]

Enrollment: 60
Study Start Date: July 2004
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Ramipril
2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
No Intervention: 2


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • biopsy-confirmed IgA nephropathy
  • proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 µmol/l

Exclusion Criteria:

  • pregnant or nursing mother, or women of childbearing potential without an effective method of birth control
  • history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor
  • evidence of clinically significant hepatic, gastrointestinal, autoimmune disease
  • history of malignancy, drug or alcohol abuse
  • participation in any previous trial on ACE inhibitor
  • taking other investigational drugs within the past 30 days
  • known history of sensitivity / allergy to ACE inhibitor

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00437463

Hong Kong
Hong Kong, Hong Kong
Sponsors and Collaborators
Study Director: Daniel Yuen Sanofi
  More Information

Responsible Party: Trial Transparency Team, sanofi-aventis Identifier: NCT00437463     History of Changes
Other Study ID Numbers: HOE498_6015
Study First Received: February 20, 2007
Last Updated: November 17, 2010

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Immunoglobulin A
Angiotensin-Converting Enzyme Inhibitors
Immunologic Factors
Physiological Effects of Drugs
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on September 21, 2017